SCHEMBL3964580

SCHEMBL3964580

CNC(=O)c1ccc2cc(-c3nc(Cl)ncc3Cl)sc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 3/20 0.44
HDAC1 Q13547 2/20 0.44
HDAC3 O15379 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.42
RET P07949 1/20 0.39
KDR P35968 1/20 0.39
RAB9A P51151 2/20 0.38
NPC1 O15118 1/20 0.38
PLK1 P53350 1/20 0.37
THRB P10828 1/20 0.37
PLAU P00749 1/20 0.36
ROCK2 O75116 1/20 0.36
LCK P06239 1/20 0.36
PCSK9 Q8NBP7 1/20 0.36
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3968816 0.90 HDAC6 (0.43) HDAC6HDAC1HDAC3HDAC2HDAC8
SCHEMBL3965404 0.86 HDAC1 (0.49) HDAC6HDAC1HDAC3HDAC2HDAC8
SCHEMBL3966800 0.77 JAK2 (0.41) HDAC6HDAC1HDAC3HDAC2HDAC8
SCHEMBL3965558 0.76 PKM (0.49) SMN1; SMN2KMT2A
SCHEMBL3970210 0.76 NPC1 (0.41) HDAC6HDAC1HDAC3HDAC2HDAC8
SCHEMBL3962466 0.76 HDAC1 (0.48) HDAC6HDAC1HDAC3HDAC2HDAC8
Hydrochloric Acid SCHEMBL3969440 0.76 FGFR1 (0.45) DYRK1A
SCHEMBL3968770 0.75 ACP1 (0.37) PCSK9
SCHEMBL3963487 0.75 RPS6KA5 (0.32) KDRBTK
Hydrochloric Acid SCHEMBL3971773 0.74 FGFR1 (0.38) RAB9ANPC1MAPTDYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1989200-B1 [4-(BENZO[B]THIOPHEN-2-YL)-PYRIMIDIN-2-YL]-AMINE DERIVATIVES AS IKK-BETA INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES LILLY CO ELI (US) 2009-07-29 EP disclosed
US-7547691-B2 [4-(Benzo[B]thiophen-2-yl) Pyrimidin-2-yl]-amine derivatives as IKK-beta inhibitors for the treatment of cancer and inflammatory diseases ELI LILLY AND COMPANY (US) 2009-06-16 US disclosed
US-20080306082-A1 [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases ELI LILLY AND COMPANY 2008-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306082-A1 [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases NFKBIA, IKBKB, IKBKG HDAC6 1478/4885HDAC1 1093/4885HDAC3 1742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.